Investors have been selling this medical device company’s shares on Friday…
The post Atomo Diagnostics (ASX:AT1) share price sinks 8% on FY21 results appeared first on The Motley Fool Australia. –
The Atomo Diagnostics Ltd (ASX: AT1) share price has been out of form on Friday.
Earlier today, the medical device company’s shares fell as much as 8% to 22.5 cents. This was in response to the release of its full year results.
Atomo Diagnostics share price falls after losses double in FY 2021
Revenue increased 25% to $6.72 million
Cost of sales up 52% to $3.3 million
Gross profit up 7% to $3.42 million
Underlying operating loss widened 101% to $4.79 million
Cash balance of ~$18 million
What happened for Atomo in FY 2021?
For the 12 months ended 30 June, Atomo reported a 25.1% increase in revenue to $6.72 million.
This was driven largely by demand for devices from customers in Europe and North America for the production of COVID-19 antibody tests.
Also supporting its sales growth was demand in Australia for Atomo branded COVID-19 rapid antibody and antigen tests and its HIV products in Australia and internationally.
What did management say?
Management was pleased with the company’s performance during a year filled with both headwinds and tailwinds.
It commented: “Atomo’s activities continued throughout FY21 nothwithstanding the COVID-19 pandemic. There were some delays in activity caused by the pandemic, for example, the global tender for HIV Self Tests run by Unitaid was substantially delayed, the consequence of which was that Atomo’s revenue from that tender was modest and primarily occured at the very end of the financial year.”
“That said, a significant portion of additional revenue was driven by demand for Atomo’s COVID-19 products in Australia and for its platforms for use by OEM customers in their own COVID-19 rapid tests internationally,” it added.
No guidance was given for the year ahead, which could be weighing on the Atomo share price a touch today.
However, management has stated that it is prioritising the continued expansion of strategic commercialisation partnerships across key global markets. This includes seeking a US market entry partnership.
In addition, it is aiming to expand its COVID-19 revenues with a core focus on the Australian market. It will also target HIV sales growth in existing territories and look to secure commercial agreements in new territories.
Should you invest $1,000 in Atomo right now?
Before you consider Atomo, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Atomo wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Here’s why the Atomo (ASX: AT1) share price flew 4% higher today
The Atomo (ASX:AT1) share price has shot up 9%. Here’s why
Ellume is making news and these ASX shares are surging, again
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.